How Are the New Lupus Nephritis Guidelines Impacting Treatment?
Recognized as National Kidney Month, March is the ideal time to learn more about the 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Recently issued, the guidelines are designed to provide healthcare providers with up-to-date guidance on the care and treatment of adults and children with lupus […]
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. This development provides hope for another treatment option for those living with lupus […]
Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study
Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the […]
Lupus Innovation Award (LIA)
The Lupus Innovation Award ($300,000 for 2 years) provides early-stage support for highly innovative approaches to major challenges in lupus research. If you are a researcher and would like to learn more about our funded research please click here.
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […]
Good News on Lupus Nephritis Discoveries from ACR Convergence 2020
November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE). AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […]
Lupus Research Alliance Grants Lupus Innovation Awards to Advance Ground-Breaking Lupus Research
NEW YORK, NY, March 23, 2023. The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants. Collectively, the seven projects led by research teams from the U.S. and Europe explore multiple components of lupus, focusing on its causes and the development of more personalized approaches to lupus treatments. […]
Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus. AlloNK […]
Lupus Research Alliance Awards $3 Million to Advance Pediatric Lupus Nephritis Diagnosis and Treatment
The Lupus Research Alliance (LRA) is pleased to announce that the 2023 Global Team Science Award (GTSA) has been granted to an exceptional multidisciplinary research team of experts in immunology, pediatric rheumatology and nephrology, genetics, and data analysis to identify drivers of lupus nephritis in children with the aim of improving its diagnosis and treatment. […]
Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024
The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that 34 presentations, including research funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be part of ACR Convergence 2024. The annual meeting of the American College of Rheumatology takes place November 14-19, at the […]
Lupus Research Alliance Grants Lupus Innovation Awards to Nine International Researchers Pushing the Boundaries of Lupus Research
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). They will conduct innovative research to uncover the underlying mechanisms and identify novel targets and pathways that could be harnessed to predict, monitor, and treat lupus, a complex autoimmune disease. The LIA […]
Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […]